U.S., Jan. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07365904) titled 'Investigating Ovulation Inhibition for Use as a Contraceptive' on Sept. 08, 2025.
Brief Summary: A single-centre, open-label, randomised, phase II study on the maintenance of ovulation inhibition after intentional application errors during 84 days of treatment with MR 130A 01 contraceptive transdermal patch
Study Start Date: Dec. 22, 2025
Study Type: INTERVENTIONAL
Condition:
Contraception
Intervention:
DRUG: MR-130A-01 contraceptive transdermal patch, containing norelgestromin (NGMN)
MR-130A-01 contraceptive transdermal patch, containing norelgestromin (NGMN)
Recruitment Status: RECRUITING
Sponsor: Mylan Pharmaceuticals In...